-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our target price to USD36 from USD54, and we trim our EPS estimates to USD2.45 from USD2.53 for 2026 and to USD2.64 from USD2.74 for 2027 in light of the guidance cut. The target price implies a 2026 P/E of 14.7x, below its historical average of 20x-22x to reflect headwinds on its key growth contributor QuantiFERON. Qiagen's preliminary Q1 2026 net sales fell 1% CER, missing the company's outlook for at least 1% growth, dragged by QuantiFERON (-5% CER) due to reduced immigration testing demand in the U.S. and Middle East. Given the slow start to the year, Qiagen downgraded 2026 guidance to 1%-2% CER sales growth from at least 5% and adjusted EPS to at least USD2.43 CER from USD2.50. We view the sales miss and lowered outlook as disappointing. We still see QuantiFERON as a main growth contributor over the long term, thus monitoring progress in other patient testing groups remains key. Full Q1 results are scheduled for May 6, 2026.